TABLE 4.
Relationships of FAP expression in tumor cells and CAFs with clinicopathological and molecular characteristics
| FAP expression (tumor cells) | FAP expression (CAFs) | |||||
|---|---|---|---|---|---|---|
| Low | High | Low | High | |||
| Variables | (n = 280, 81.4%) | (n = 64, 18.6%) | p‐value | (n = 230, 66.9%) | (n = 114, 33.1%) | p‐value |
| Sex | ||||||
| Male (192) | 156 (81.2) | 36 (18.8) | 0.992 | 112 (58.3) | 80 (41.7) | < 0.001 |
| Female (152) | 124 (81.6) | 28 (18.4) | 118 (77.6) | 34 (22.4) | ||
| Age | ||||||
| ≤ 69 years (162) | 139 (85.8) | 23 (14.2) | 0.065 | 114 (70.4) | 48 (29.6) | 0.234 |
| ≥ 70 years (182) | 141 (77.5) | 41 (22.5) | 116 (63.7) | 66 (36.3) | ||
| Smoking | ||||||
| No (135) | 110 (81.5) | 25 (18.5) | 0.996 | 109 (80.7) | 26 (19.3) | < 0.001 |
| Yes (209) | 170 (81.3) | 39 (18.7) | 121 (57.9) | 88 (42.1) | ||
| Stage | ||||||
| 0‐I (231) | 195 (84.4) | 36 (15.6) | 0.056 (0–I vs. II–III) | 173 (74.9) | 58 (25.1) | < 0.001 (0–I versus II–III) |
| II (45) | 35 (77.8) | 10 (22.2) | 23 (51.1) | 22 (48.9) | ||
| III (68) | 50 (73.5) | 18 (26.5) | 34 (50) | 34 (50) | ||
| Histology | ||||||
| ADC (260) | 208 (80) | 52 (20) | 0.372 (ADC vs. SCC) | 194 (74.6) | 66 (25.4) | < 0.001 (ADC versus SCC) |
| SCC (64) | 55 (85.9) | 9 (14.1) | 24 (37.5) | 40 (62.5) | ||
| Others (20) | 17 (85) | 3 (15) | 12 (60) | 8 (40) | ||
| Lymphocytic invasion | ||||||
| No (300) | 248 (82.7) | 52 (17.3) | 0.169 | 210 (70) | 90 (30) | 0.002 |
| Yes (44) | 32 (72.7) | 12 (27.3) | 20 (45.5) | 24 (54.5) | ||
| Vascular invasion | ||||||
| No (250) | 212 (84.8) | 38 (15.2) | 0.013 | 190 (76) | 60 (24) | < 0.001 |
| Yes (94) | 68 (72.3) | 26 (27.7) | 40 (42.6) | 54 (57.4) | ||
| Pleural invasion | ||||||
| No (260) | 216 (83.1) | 44 (16.9) | 0.212 | 185 (71.2) | 75 (28.8) | 0.004 |
| Yes (84) | 64 (76.2) | 20 (23.8) | 45 (53.6) | 39 (46.4) | ||
| p53 IHC | ||||||
| Negative (231) | 193 (83.5) | 38 (16.5) | 0.187 | 172 (74.5) | 59 (25.5) | < 0.001 |
| Positive (113) | 87 (77) | 26 (23) | 58 (51.3) | 55 (48.7) | ||
| PD‐L1 IHC | ||||||
| Negative (287) | 248 (86.4) | 39 (13.6) | < 0.001 | 209 (72.8) | 78 (27.2) | < 0.001 |
| Positive (57) | 32 (56.1) | 25 (43.9) | 21 (3.8) | 36 (63.2) | ||
Abbreviations: ADC, adenocarcinoma; CAFs, cancer‐associated fibroblasts; FAP, fibroblast‐activating protein; IHC, immunohistochemistry; PD‐L1, programmed death ligand 1; SCC, squamous cell carcinoma.